Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cardiac Resynchronization Therapy · 1 trial · 1 indication
This procedure will take approximately 30 minutes prior to implant of a CRT system. At completion of this study the patient is not followed and will be transferred to another study if enrolled in a clinical or followed as a routine implant by the center.
| Arm | Type | Description |
|---|---|---|
| Cardiac Resynchronization Therapy (CRT) | EXPERIMENTAL | Implanting device to measure delays between paced chambers in heart failure patients. |
| Name | Type | Description |
|---|---|---|
| Cardiac Resynchronization Therapy | PROCEDURE | Implanting device to measure delays between paced chambers in heart failure patients. |
Inclusion Criteria: * Patient is greater than 18 years of age. * The patient or the patient's legally authorized representative is willing to give informed consent. * CRT indicated guidelines. * Patient is receiving a Medtronic IPG or ICD. Exclusion Criteria: * Patients who are pregnant. * Patien...
Top 12 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 6 | PHASE3 | Ziltivekimab, NNC0487-0111, CDR132L, NNC0537-1482 |
| AstraZeneca PLC | AZN | 6 | PHASE3 | Baxdrostat |
| Cytokinetics, Incorporated | CYTK | 2 | PHASE3 | Omecamtiv mecarbil, CK-4021586 |
| Amgen Inc. | AMGN | 1 | PHASE3 | Maridebart cafraglutide |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07328948 |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Vericiguat |
| Bristol-Myers Squibb Company | BMY | 1 | PHASE2 | BMS-986435 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE1 | HJB647 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX45 |
| Colorado Prevention Center | BAYRY | 2 | PHASE3 | Finerenone |
| BioCardia, Inc. | BCDA | 2 | PHASE1 | CardiALLO |
| Windtree Therapeutics | WINT | 1 | PHASE1 | Istaroxime |